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Abstract    
Objective: To compare the prevalence of the main comorbidities in two large cohorts of 
patients with Primary Sjögren’s Syndrome (pSS) and Systemic Lupus Erythematosus 
(SLE), with focus on cardiovascular (CV) diseases.   
Methods: Cross-sectional multicenter study where the prevalence of more relevant 
comorbidities in two cohorts was compared. Patients under follow-up from the 
SJOGRENSER (Spanish Rheumatology Society Register of pSS) and RELESSER 
(Spanish Rheumatology Society Register of SLE) registries, and who fulfilled the 2002-
AECG and 1997-ACR classification criteria, respectively, were included. A binomial 
logistic regression analysis was carried out to explore potential differences, making 
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general adjustments for age, sex and disease duration and specific adjustments for each 
variable, including CV risk factors and treatments, when it was judged appropriate. 
Results: A total of 437 pSS patients (95% female) and 2,926 SLE patients (89% female) 
were included. Mean age: 58.6 (p55-p75: 50.0-69.9) and 45.1 years (36.4-56.3), 
respectively (p<0.001). Disease duration: 10.4 (6.0-16.7) and 13.0 years (7.45-19.76), 
respectively (p<0.001). Smoking, dyslipidemia and arterial hypertension were 
associated less frequently with pSS [OR: 0.36 (95%CI:0.28-0.48), OR: 0.74 (0.58-0.94) 
and OR: 0.50 (0.38-0.66), respectively] as were life-threatening CV events (i.e., stroke 
or myocardial infarction) [OR: 0.57 (0.35-0.92)]. Conversely, lymphoma was associated 
more frequently with pSS [OR 4.41 (1.35-14.43)]. The prevalence of severe infection 
was lower in pSS than in SLE (10.1% vs 16.9%, p<0.001; OR: 0.54 (0.39-0.76). 
 
Conclusions: pSS patients have consistently less serious CV comorbidity burden and a 
lower prevalence of severe infection than those with SLE. In contrast, their risk of 
lymphoma was greater.  
  
Key words 
Primary Sjögren’s syndrome, Systemic Lupus Erythematosus, comorbidity, 
cardiovascular diseases, infection  
 
Significance and Innovations: - 
- This first large-scale comparative study between pSS and SLE contributes to a 
better understanding of the differences and similarities between two systemic 
immune-mediated inflammatory rheumatic conditions  
-pSS patients have consistently less serious CV comorbidity burdens than those with 
SLE 
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- In contrast, the risk of lymphoma in pSS exceeds that seen in SLE patients  
 
 
Primary Sjögren’s syndrome (pSS) is an autoimmune disorder characterized by chronic 
multisystem inflammation that shares certain pathophysiology and clinical features with 
Systemic Lupus Erythematosus (SLE). Although pSS is one of the most common 
rheumatic autoimmune diseases (1), reliable data regarding the prevalence of specific 
medical comorbidities in patients with pSS remain scarce (2). 
Although increased atherosclerotic risk has been well established in other rheumatic 
autoimmune systemic diseases such as SLE (3, 4) only limited evidence is available for 
pSS. A higher prevalence of several cardiovascular (CV) risk factors, including 
hyperlipidemia, hypertension and metabolic syndrome has been noted in patients with 
pSS compared to age- and sex-matched healthy controls (5-7). Furthermore, higher 
prevalence of early subclinical atherosclerosis in pSS has similarly been observed in 
several studies (8,9,10). However, the issue of whether the presence of certain 
cardiovascular risk factors translates into an increased likelihood of CV events in pSS 
patients has not been studied in sufficient detail. 
There are no comparative studies examining the most relevant comorbidities in patients 
with pSS versus those with SLE. Such studies could contribute not only to a better 
delineation of CV and/or lymphoma risk factors and other comorbidities, but also 
improve our understanding of the similarities and differences between these two 
immune-mediated, systemic rheumatic diseases. 
In this study we analyzed the differences and similarities concerning the prevalence of 
certain comorbidities conditions in two large nation-wide cohorts of patients suffering 
SLE or pSS drawn from the Spanish Rheumatology Society SLE (RELESSER) and 
Spanish Rheumatology Society pSS (SJOGRENSER) Registries. This study was 
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conducted under the aegis of the Autoimmune Systemic Disease Study Group of the 
Spanish Society of Rheumatology (EAS-SER) and took advantage of the identical 
definitions of comorbidities used in the two registers, as well as the same network of 
researchers involved in both. In the present analysis, we have made a special emphasis 






The methodology used, the definitions of the disease-related variables, and general 
characteristics of both registries (RELESSER and SJOGRENSER) have been 
previously described in detail (11,12). Briefly, the RELESSER is a nation-wide 
multicenter, hospital-based registry. It has 2 parts: an initial cross-sectional phase 
(RELESSER-TRANS) and a further prospective cohort study (RELESSER-PROS) that 
remains ongoing. This study included patients from 45 rheumatology departments 
across Spain with substantial experience in the management of SLE. Moreover, it 
includes comprehensive clinical data for every patient. Only the cumulative data from 
the RELESSER-TRANS were used in the current analysis. The procedure of inclusion 
was not random in RELESSER and the centers were invited to include all patients 
whose medical records were available.  
SJOGRENSER is also a multicenter descriptive transversal study of pSS patients under 
active follow-up at 33 rheumatology departments similarly distributed throughout 
Spain. Patients under active follow-up were included randomly from an anonymized list 
provided by each department. 
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The two cohorts were assembled by the EAS-SER Group. Both shared the same 
network of researchers and both were built using a high degree of standardization in 
defining their respective variables (11,12).  
Both registries were approved by the institutional research review boards at all 
participating centers. Informed consent was obtained from every patient included.  The 
studies were conducted in accordance with the Helsinki Declaration. 
All pSS and secondary SS (sSS) patients fulfilled the 2002-American-European 
Consensus Group (AECG) criteria for the classification of SS (13), and all SLE patients 
met the 1997-ACR criteria (14). 
In both registries, extensive information about cumulative comorbidity conditions was 
collected, using identical definitions for all of the comorbidities included in this 
analysis, as detailed below. 
Design  
Cross-sectional multicenter study where the cumulative prevalence of comorbidities 
between two patient cohorts was compared.   
Definitions  
CV risk factors were defined as follows: Smoking was categorized as follows: current 
or ex-smoker, and never smoked. Diabetes: previous diagnosis or 2 fasting serum 
glucose levels 126 mg/dL and/or antidiabetic drugs. Dyslipidemia: total cholesterol 240 
mg/dL and/or low-density lipoprotein > 130 mg/dL and/or triglycerides160 mg/dL 
and/or intake of lipid-lowering drugs. Hypertension was classified using the following 
World Health Organization (WHO) definitions: systolic blood pressure 140 mm Hg 
and/or a diastolic blood pressure 90 mm Hg on 2 occasions or receiving 
antihypertensive treatment (15). 
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On the other hand, a CV event was defined as the presence of at least 1 of following: 
ischemic heart disease, including myocardial infarction and/or angina pectoris based on 
clinical diagnosis and ischemic changes in the electrocardiogram and/or specific 
changes in cardiac enzymes and/or typical findings in a coronary angiography; 
clinically diagnosed heart failure and/or based on chest radiography; cerebral vascular 
accident based on an unequivocal previous diagnosis or on the presence of clinical 
manifestations and/or supported by an imaging procedure; and peripheral artery disease 
supported by the presence of clinical manifestations confirmed by an imaging 
procedure.  
 
Other comorbidity definitions include: Fibromyalgia (FM) according to the 1990-ACR 
criteria (16); severe infection: infections requiring hospitalization; osteoporotic 
fractures: if clinically recorded as such; lymphoma: through involved tissue biopsy.  
Statistical analysis  
With the aim of improving comparability between the two cohorts, we performed the 
main analysis, including only those patients under active follow-up from the 
RELESSER cohort, since the SJOGRENSER registry include only living patients under 
active follow-up. However, given that around one-third of SLE patients die due to CV 
causes and since - in contrast to pSS - CV mortality is higher in SLE patients than in the 
general population, we decided to conduct a sensitivity analysis, including also those 
patients who had died. In this manner, we sought to avoid any bias related to the loss of 
patients that died due to severe CV events in the SLE cohort. 
Additionally, to avoid “overlapping” patients, we decided to exclude from the main 
analysis those patients with sSS from the SLE group.  
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Values related to categorical variables are expressed as percentages. Continuous 
variables are considered as medians and interquartile ranges. Comparisons were done 
using a chi-square test for categorical data and Kruskal-Wallis tests for continuous data. 
Associations were studied through a binomial logistic regression analysis. Results are 
expressed as crude Odds Ratio (OR) and adjusted OR. All of the comparisons were 
adjusted for age, sex and disease duration; specific adjustments for each variable, 
including CV risk factors and treatments, were made when deemed appropriate. All 
analyses were carried out using Stata 13.1 and SPSS 21.0. 
 
Results 
A total of 437 patients with pSS were included, 95% of them women and 93% 
Caucasian, with a median age at inclusion of 59 years and a median age at diagnosis of 
50 years. The median score for ESSDAI (EULAR Sjögren’s Syndrome Disease Activity 
Index) was 2 (p25-p75:0-4). Less than 5% of patients developed visceral involvement, 
using ESSDAI items, and 56% exhibited hematologic involvement. A total of 102 
patients (23.3%) had hypocomplementemia (low C3 or low C4, anytime) and 26 (6 %) 
carried some type of antiphospholipid antibodies.  
In parallel, all patients fulfilling the ACR-97 SLE criteria included in RELESSER under 
active follow-up were included in the analysis. Thus, there was a total of 2,926 patients 
of whom 2,523 (89.9% female) were SLE patients without sSS.   
A comprehensive description of clinical characteristics and comorbidities of the entire 
RELESSER cohort has previously been published (17).  
A total of 2,926 SLE patients (89% female) were included in this analysis, 93.3% of 
them Caucasian, with a mean age at inclusion of 45.1 years (36.4-56.3). The main 
clinical characteristics of this RELESSER subgroup, namely, SLE patients under active 
follow-up and without sSS (corresponding to the present analysis) at the time of 
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inclusion in the registry were as follows:  median score for SELENA-SLEDAI 
(SELENA-Systemic Lupus Erythematosus Disease Activity Index) 2 (p25-p75:0-4), 
SLICC/ACR Damage Index: 0 (0-1); lupus nephritis was present in 29.9%, 1.3% of 
patients were in a dialysis program and 1.5 % had undergone renal transplant.  A total 
of 1934 patients (78 %) had hypocomplementemia (low C3 or low C4, anytime) and 
960 (55.1%) any kind of antiphospholipid antibodies.  
The comparative sociodemographic and chronological characteristics of pSS versus 
SLE without sSS are shown in Table 1. It is worth noting the differences in the mean 
age of patients upon enrollment in the registry (median: 58.6 years in pSS versus 44.5 
years for SLE, p<0.001). Remarkable differences between SLE and pSS were also 
observed in cumulative treatments, as shown in Table 2, with more SLE patients 
undergoing some glucocorticoid, antimalarial and/or immunosuppressive treatment, 
except in the case of rituximab. Moreover, significantly fewer patients with pSS were 
hospitalized due to disease activity, compared with SLE patients [(17.2% vs. 53.2%, p 
<0.001; OR: 0.19 (95%CI: 0.15-0.24)].  
A comparative analysis of the prevalence of comorbidities is shown in Table 3. Classic 
CV risk factors such as tobacco use, dyslipidemia and arterial hypertension were less 
prevalent in pSS and the adjusted ORs were: 0.39 (95%CI:0.29-0.51), 0.77 (0.61-0.98) 
and 0.51 (0.39-0.66), respectively as were life-threatening CV events (i.e., stroke or 
myocardial infarction) [adjusted OR: 0.61 (0.38-0.93)] (Table 3). When we also 
adjusted for hypocomplementemia, no relevant changes in the Odd Ratios were 
observed. Conversely, adjusting for antiphospholipid antibodies resulted in the loss of 
statistical significance for all CV event differences.  
The prevalence of severe infection was lower in pSS than in SLE (10.1% vs 16.9%, 
p<0.001; crude OR: 0.55 (0.40-0.77) and the OR adjusted for age, sex, disease duration 
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was :0.62 (0.44-0.86) (p=0.008), although this difference lost statistical significance 
when also adjusted for treatments (glucocorticoids, hydroxychloroquine and 
immunosuppressives). Conversely, lymphoma was associated more frequently with pSS 
[adjusted OR 4.41 (95%CI: 1.35-14.43)]. On the other hand, FM was also more 
frequently observed in pSS patients [adjusted OR: 2.43 (1.70-3.49)]. 
An alternative analysis was carried out that included patients with sSS who also existed 
in the SLE group, and the results are shown in Supplementary Materials (Table 4). In 
short, only one difference lost statistical significance; i.e., stroke, with an adjusted OR 
of 0.56 (95%CI: 0.30-1.04). Additionally, it is worth noting that the OR of FM 
prevalence in pSS patients versus those with SLE decreased [from 2.43 (1.70-3.49) to 
1.98 (1.42-2.76)] when the former were included in the analysis. 
Finally, an additional sensitivity analysis was carried out that also took into account 
those patients in SLE group who had died. This was done in an attempt of improve the 
capture of serious CV events in SLE by reducing bias related to CV death in SLE 
patients.  These results are shown in Table 5 (Supplementary Materials). The adjusted 
ORs (pSS/SLE) for cardiac failure prevalence and severe infection reached statistical 
significance when the dead patients from the RELESSER registry were included in the 
analysis [ORs: 0.49 (95%CI: 0.27-0.89) and 0.66 (95%CI: 0.46-0.96), respectively]. 
Interestingly, the OR for differences in the presence of lymphoma decreased, losing the 
statistical significance [from 4.41 (1.35-14.43) to 2.50 (0.92-6.80)].   




In our comparative analysis, we found a higher prevalence of serious CV comorbidities 
in patients with SLE than in those with pSS. These results are in line with the absence 
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of an increase of mortality in pSS, suggested by several studies (18, 19) as well as with 
a lesser degree of damage observed in pSS when comparing with SLE. (20). 
Furthermore, the lower rate of disease-related hospitalization observed in our study 
seems to confirm that pSS is a less severe disease than SLE, at least in our environment 
and as defined by the 2002-AECG criteria. In fact, this feature probably has an impact 
on the development of comorbidities. It is worth noting that the difference in the 
prevalence of severe CV comorbidities was more consistent when SLE patients without 
sSS were compared against those with pSS. This last observation is consistent with the 
less severe SLE in patients with associated sSS versus those without sSS, which has 
been reported by several groups (21,22). 
The prevalence of lymphoma constitutes an exception, being more frequently observed 
in pSS in the current comparative analysis. However, the prevalence of lymphoma 
(1.6%) was not markedly high in the SJOGRENSER registry. This result is in line with 
the low prevalence of lymphoma reported by Malladi et al, who used the same 2002-
AECG classification criteria in analyzing a large international registry of pSS patients 
(23). The use of alternative classification criteria may, obviously, lead to differences in 
the observed prevalence of this complication in pSS. The ratio for lymphoma was 
approximately 4 times higher in pSS compared with SLE in our analysis, a difference 
that did not change significantly when adjusted for immunosuppressor and antimalarial 
use. Interestingly, when patients with sSS from the RELESSER cohort were included, 
the difference in the prevalence of lymphoma did not change in any relevant way. This 
observation suggests that in SLE, the risk of lymphoma is not linked to the presence of 
sSS. Our results are consistent with a recent case-control study from a large SLE cohort, 
in which no difference was found in the prevalence of sSS between SLE patients with or 
without B-cell lymphoma (24).  
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While several lines of evidence support an increase of CV events in SLE (25- 28), this 
is not the case, at least not to the same extent as with pSS. Although classic CV risk 
factors are indeed higher in pSS patients, a corresponding increase in CV events is less 
clear. Bartoline et al. actually observed that cerebrovascular events and myocardial 
infarction were significantly more common in patients with pSS versus age-matched 
healthy women (2.5% vs. 1.4% and 1.0% vs. 0.4%, respectively) when analyzing a 
large multicenter cohort of pSS (27). In contrast, several studies have not  found any 
differences in the prevalence of CV events when compared with the general population 
(2, 29-31).   
In our study, we found that the OR of CV events was around 50% less in patients with 
pSS versus those with SLE. These results are consistent with the absence of increased 
CV mortality associated with pSS when compared with general population and conform 
to most studies carried out to date (18,19). In contrast, the mortality rate is clearly 
higher in SLE patients and CV diseases remain a principal cause of death in this 
condition (32).  
Several classical CV risk factors were more prevalent in SLE (namely arterial 
hypertension, dyslipidemia and tobacco smoking) in our study.  Worth noting is the fact 
that the difference between pSS and SLE across all types of CV events was not entirely 
explained by differences in the classic CV risk factors included in our analysis, 
suggesting that SLE-intrinsic factors are probably involved. In contrast and 
interestingly, a study carried out comparing pSS with a control group did not find any 
differences in intima medial thickness after adjusting for classical cardiovascular risk 
factors. This suggests that perhaps the disease-related factors are not as important in 
atherosclerosis associated with pSS (8).  
Although some studies have found higher mean levels of C-reactive protein (CRP) in 
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pSS (31), it can be assumed in general terms that pSS is, in fact, a disease in which the 
concentration of acute-phase protein serum CRP is not elevated (35). It is tempting to 
speculate that the inflammatory burden might be lower in pSS than SLE. In fact, many 
patients with SLE increased levels of CRP, particularly with arthritis and serositis, and 
CRP is associated with disease activity in these organs (35,37). Bearing in mind that 
CRP, particularly high-sensitivity CRP, has been associated with atherosclerosis both in 
the general population (38) and in SLE patients (39, 40), this difference could plausibly 
explain the  revalence of CV disease in pSS and SLE. Unfortunately, we do not have 
comparative data about CRP in our cohorts.  
Additionally, complement activation is more prevalent in SLE than in pSS (38), which 
is confirmed in our own study. The complement system has been associated with 
subclinical arteriosclerosis and atheroma plaque progression in SLE (39, 40). However, 
when we adjusted for hypocomplementemia, the Odd Ratios did not change in a 
relevant way for any CV event, suggesting that this variable does not explain the 
differences between pSS and SLE. In fact, the association of hypocomplementemia with 
CV events in SLE remains controversial (25, 26).  
On the other hand, there is a higher risk of thrombosis in patients with SLE 
compared to pSS, at least in terms of venous thrombosis. This suggests the existence 
of a prothrombotic state in SLE, which would be less relevant in pSS (42).  
In this regard, several research groups have noted an increase in homocysteine in 
SLE patients, a risk factor of CV diseases apparently not present in pSS. In fact, 
homocyteine’s role in the progression of atherosclerosis in SLE has been posited by 
several longitudinal studies (39, 43, 44). Additionally, the prevalence of 
antiphospholipid antibodies and antiphospholipid syndrome is higher in SLE than in 
pSS patients (45), a difference again clearly shown in our study. Further to this, our 
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group has recently published an analysis concerning CV events in patients from the 
RELESSER registry, in which antiphospholipid antibody positivity was associated 
with CV events in a multivariate analysis (25). Remarkably, at least in the present 
analysis, adjusting for antiphospholipid antibodies entails the loss of statistical 
significance for all Odd Ratios corresponding to CV events.  
Another interesting finding of our study relates to tobacco smoking. Several reports 
indicate that tobacco smoking serves as a protective factor for pSS (30, 46). In contrast, 
tobacco is well known risk factor for SLE (47). Our own study is a clear confirmation of 
the opposite impact of smoking on two rheumatic immune-mediated inflammatory 
diseases. However, when we adjusted our analysis for tobacco use, differences in CV 
events between LES and pSS remained.     
In contrast with SLE, the prevalence of severe infection in pSS is largely unknown. We 
have found a prevalence of infection of 10% in our pSS cohort. Based on our analysis, 
the OR of this serious complication was approximately 40% less in pSS than in SLE, 
although the difference did not maintain statistical significance when adjusted for 
therapies (immunosuppressant drugs, GC and antimalarial use). This observation 
suggest that factors related to treatments, more than the disease itself, could be involved 
in the greater risk for infection recorded in SLE patients. The discovery that significant 
differences were more evident when dead patients were included in the SLE group 
suggests that the prevalence of severe infection in SLE is under-estimated in this 
analysis.   
FM is a comorbidity condition that negatively impacts the quality of life in patients with 
SLE and pSS (48). Most, but not all, of the observational cohort studies that have 
included patients with both SLE and pSS patients have observed a higher prevalence of 
FM in pSS versus SLE (49-51). However, only in this comparative analysis were 
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adjustments for sex, age and disease duration carried out, thus confirming and 
reinforcing previous data. Recently, the relationship between pSS and FM was further 
underscored by the findings in a specifically conducted analysis drawing from 
RELESSER cohort, in which sSS was identified as a risk factor for fibromyalgia in SLE 
(52). Furthermore, when we included patients with sSS from the RELESSER cohort in 
the present analysis, the OR comparing the prevalence of FM in pSS versus SLE 
decreased, while still favoring pSS.  Although it is clear from the literature that FM 
and/or chronic widespread pain is frequently observed in all autoimmune systemic 
rheumatic diseases (48), the prevalence of and pathogenic factors involved in each 
probably differ.  
Very limited information is available on the occurrence of fracture rates in patients with 
pSS. Gravani et al found a prevalence of fractures of 12.5%, a percentage not 
significantly different compared to healthy controls (9). In our study, which involved a 
larger and more representative sample of pSS using the same classification criteria, the 
prevalence of fracture was not very different; i.e., 8.6%. Despite the prolonged use of 
GCs in SLE patients, we did not find any differences in the prevalence of osteoporotic 
fractures between the pSS and SLE cohorts.  This somewhat unexpected result deserves 
explanation, but unfortunately, the lack of covariates related to fracture risk in our study 
does not allow for further analysis.  
Our study has certain limitations that must be pointed out. First of all, the results of this 
analysis are limited by the bias inherent to its transversal design. Second, the registries 
from which the cohorts are derived, RELESSER and SLOGRENSER, were not 
specifically designed for the purposes of comorbidities comparative analysis and thus 
several covariates are missing.  
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There are certain differences in the design of both registries that deserve further 
mention. Patients included in SJOGRENSER were randomly selected, thus forming a 
highly representative sample of pSS from Spanish rheumatology clinics. In contrast, 
RELESSER was a consecutive patients registry, including deceased individuals and 
those lost to follow up. In our view, however, the large number of patients ultimately 
included in RELESSER assures its representativeness. To enable a comparative 
analysis, we exclude from the RELESSER group all deceased individuals and those lost 
for follow-up. However, this selection, given the well-known low mortality rate 
associated with pSS, could result in an infra-estimation of serious comorbidity in the 
SLE group as well as severity differences. In fact, as is shown in Supplementary 
Materials, the adjusted OR for cardiac failure and infection reached significance when 
these patients where included in the analysis, increasing the prevalence differences, and 
favoring SLE. Interestingly, no changes appeared in the OR of strokes.  
In addition, it is plausible that patients with more severe pSS have higher levels of 
comorbidity, as has been observed in studies examining the prevalence of lymphoma 
(19). Despite the random nature of their selection, the number of severe pSS patients 
was not sufficient in our cohort to address this question. Nonetheless it is important to 
note that there are no universally accepted criteria for defining severe pSS, making it 
difficult to carry out this type of analysis.  
In summary, we have shown that pSS patients have a consistently less serious CV and 
infectious comorbidity burden compared to those with SLE. In contrast, their risk of 
lymphoma exceeds that seen in SLE patients.  
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Table 1: Sociodemographic differences (pSS vs. SLE without sSS) 
 pSS SLE OR (95%CI) 
Female sex, N (%)  416 (95.2) 2,268 (89.9) 0.45 (0.28 -0.71) 
Caucasian, N (%) 408 (93.4) 2,274  (92.9) - 
Age at diagnosis, median (p25–p75) 50.2 (41.9-59.3) 32.0 (23.6-42.1) 1.08 (1.07-1.09) 
Age at inclusion , median (p25–p75) 58.6 (50.0-69.9) 44.5 (35.6-54.9) 1.06 (1.06-1.07) 
Disease duration , median (p25–p75) 10.4 (6.0-16.7) 12.7 (7.2-19.6) 0.98 (0.97-0.99) 
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Table 2: pSS and SLE (without sSS) cumulative treatment comparisons 
 
 pSS SLE OR (95%CI) 
HCQ (current or ever) : N(%) 219 (50.9) 2,085  (87.5) 0.15 (0.12-0.19) 
GC (current or ever) : N(%) 213 (49.4) 2,108  (87.9) 0.13 (0.11-0.17) 
Current GC dosage *    
         < = 10mg/daily : N(%) 114 (62.3) 151 (47.9) ref 
         10-30 mg/daily : N(%) 29 (15.8) 102 (32.4) 0.38 (0.23-0.61) 
          >  30mg/daily : N(%) 40 (21.9) 62 (19.7) 0.85 (0.54-1.36) 
Azathioprine: N(%) 45 (10.1) 753 (31.8) 0.25 (0.18-0.35) 
Methotrexate : N(%) 57 (13.5) 407 (17.1) 0.75 (0.55-1.01) 
Mycophenolate : N(%) 17 (3.9) 385 (16.3) 0.21 (0.13-0.35) 
Ciclophosphamide : N(%) 13 (3.0) 521 (21.9) 0.11 (0.06-0.20) 
Rituximab : N(%) 31 (7.3) 158 (6.6) 1.10 (0.74-1.63) 
*Prednisone or equivalent  
pSS: primary Sjögren’s syndrome; sSS: secondary SS; SLE: Systemic Lupus Erythematosus.  
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Table 3: Comparative prevalence of comorbidities (pSS vs. SLE without sSS): Results from logistic 
regression analysis 











Hypertension 112 (25.6) 673 (26.8) 0.94 (0.75-1.19) 0.50 (0.38-0.66) - 
Diabetes 28 (6.4) 106 (4.2) 1.54 (1.00-2.37) 0.79 (0.49-1.27) - 
Dyslipidemia  145 (33.2) 732 (30.2) 1.15 (0.92-1.43) 0.74 (0.58-0.94) - 
Heart failure 13 (2.9) 66 (2.64) 1.13 (0.62-2.07) 0.70 (0.37-1.33) ND 





14 (3.2) 48 (1.93) 1.68 (0.92-3.07) 0.98 (0.44-2.07) GC, smoking 
HBP, 
dyslipidemia 
Stroke 15 (3.4) 120 (4,8) 0.70 (0.41-1.22) 0.51 (0.27-0.96) GC, smoking 
HBP, 
dyslipidemia 
Any CV event  30 (6.8) 203 (8.0) 0.84 (0.57-1.26) 0.57 (0.35-0.93) GC, smoking 
HBP, 
dyslipidemia 
Fibromyalgia 64 (14.6) 129 (5.2) 3.10 (2.26-4.27) 2.43 (1.70-3.49) ND 
Osteoporotic fracture 37 (8.6) 139  (5.7) 1.56 (1.07-2.28) 0.94 (0.61-1.46) GC 
Smoking (any time)  110 (25.3) 951 (41.2) 0.33 (0.25-0.43) 0.36 (0.28-0.48) - 
Cancer (except 
lymphoma) 
21 (4.8) 104 (4.11) 1.18 (0.73-1.91) 0.72 (0.43-1.21) - 
Lymphoma 7 (1.6) 10 (0.4) 4.10 (1.55-10.83) 4.41 (1.35-14.43) IS, HCQ  
Severe infection  44 (10.1) 403 (16.9) 0.55 (0.40-0.77) 0.85 (0.58-1.25) GC, IS, HCQ 
*OR pSS vs. SLE, adjusted just by sex, age and disease duration, if not otherwise stated in the right column 
**further specific adjustments for each variable when applicable. ND: not done.  
pSS: primary Sjögren’s syndrome. sSS: secondary SS; SLE: Systemic Lupus Erythematosus. CV: cardiovascular; 
HBP: high blood pressure; HCQ: hydroxychloroquine; GC: glucocorticoids; IS: immunossupressors 
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Table 4: Comparative prevalence of comorbidities (pSS versus SLE , including patients with sSS) 




p value  OR (95%CI) p value OR adjusted* specific 
adjust** 




< 0.001 0.51 (0.39-0.66) 
 
- 

























































Fibromyalgia 64 (14.6) 186 (6.5) 
 
<0.001 2.47 (1.82-3.35) 
 
<0.001 1.98 (1.42-2.76) 
 
ND 















lymphoma 7 (1.6) 13 (0.4) 0.004 3.96 (1.55-10.11) 0.004 4.77 (1.56-14.75) 
 
IS, HCQ  
Severe infection  44 (10.1) 606  (18.5) <0.001 0.51 (0.37-0.70) 0.214 0.79 (0.54-1.15) 
 
GC, IS, HCQ 
*OR pSS versus SLE, adjusted just by sex, age and disease duration, if not otherwise stated in the right column 
**further specific adjust for each variable when applicable 
pSS: primary Sjögren’s syndrome. sSS: secondary SS; SLE: Systemic Lupus Erythematosus. CV: 
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Table 5: Comparative prevalence of comorbidities (pSS versus SLE without sSS but including all RELESSER dead 
patients) 




p value  OR (95%CI) p value OR adjusted* specific 
adjust** 




< 0.001 0.46 (0.35-0.60) 
 
- 





















































































































IS, HCQ  








GC, IS, HCQ 
*OR pSS versus SLE, adjusted just by sex, age and disease duration, if not otherwise stated in the right column 
**further specific adjust for each variable when applicable 
pSS: primary Sjögren’s syndrome. sSS: secondary SS; SLE: Systemic Lupus Erythematosus. CV: cardiovascular; 
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